Inhibition of Smad3 activity by cyclin D-CDK4 and cyclin E-CDK2 in breast cancer cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

1. Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma.Cancer cell international · 2024
   Article
2. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Oncotarget · 2014
   Review
3. ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
   Article

Corrections and comments

• Comment on
  Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.2010

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as